<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>BioMed Israel</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Resilience overcomes war, capital challenges in Israel</title>
      <description>
        <![CDATA[Despite the ongoing war, speakers at Biomed Israel this week reported that business and investment in Israel’s med-tech industry continues largely unchanged. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/708592</guid>
      <pubDate>Fri, 24 May 2024 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/708592-resilience-overcomes-war-capital-challenges-in-israel</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Geographic-regions/Middle-East/Israel-flag.webp?t=1588688540" type="image/png" medium="image" fileSize="503255">
        <media:title type="plain">Israeli flag</media:title>
      </media:content>
    </item>
    <item>
      <title>AI-focused innovation lab aims to advance antibody discovery</title>
      <description>
        <![CDATA[Pharma and tech companies including Amazon Inc., Astrazeneca plc, Pfizer Inc., Merck & Co. Inc. and Teva Inc. are partnering with an innovation lab based in Israel to accelerate artificial intelligence (AI) driven antibody discovery. Rehovot, Israel-based Aion Labs recently launched a venture hub for innovators and scientists from around the world.]]>
      </description>
      <guid>http://www.bioworld.com/articles/518806</guid>
      <pubDate>Fri, 13 May 2022 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/518806-ai-focused-innovation-lab-aims-to-advance-antibody-discovery</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2022/05-13-Aion-Labs.webp?t=1652473495" type="image/png" medium="image" fileSize="1661290">
        <media:title type="plain">Aion Labs presents at Biomed Israel</media:title>
        <media:description type="plain">At the Biomed Israel conference, Aion Labs CTO Yair Benita led a track exploring the use of AI and machine learning for drug development.</media:description>
      </media:content>
    </item>
    <item>
      <title>Medtech 2032: Where is the industry heading?</title>
      <description>
        <![CDATA[Ten years from now, what medical technologies will generate the most economic value and where is the industry heading? At the annual Biomed Israel conference, held in Tel Aviv, health care, pharmaceutical and technology advisor, and board director Sandra Morgan examined research from consulting firm McKinsey & Co. and beyond on the biggest innovation trends in the sector.]]>
      </description>
      <guid>http://www.bioworld.com/articles/518677</guid>
      <pubDate>Tue, 10 May 2022 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/518677-medtech-2032-where-is-the-industry-heading</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2022/05-10-Biomed-Israel-conference.webp?t=1652218113" type="image/png" medium="image" fileSize="1590314">
        <media:title type="plain">People congregating in the conference hallway</media:title>
        <media:description type="plain">The annual Biomed Israel conference is being held in Tel Aviv.</media:description>
      </media:content>
    </item>
    <item>
      <title>Israeli med-tech innovators told to adapt strategy or face no exit</title>
      <description>
        <![CDATA[At the annual Biomed Israel conference, held in Tel Aviv, Eyal Lifschitz, co-founder of Israeli venture capital fund Peregrine Venture, urged entrepreneurs to adapt their business strategy or face a long, difficult road to exit. With strategic companies increasingly favoring companies later in development, Lifschitz advised innovators to expand their vision beyond the traditional buyers.]]>
      </description>
      <guid>http://www.bioworld.com/articles/518673</guid>
      <pubDate>Tue, 10 May 2022 13:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/518673-israeli-med-tech-innovators-told-to-adapt-strategy-or-face-no-exit</link>
      <media:content url="https://www.bioworld.com/ext/resources/BMT-source/2022/05-10-Biomed-Israel-Eyal-Lifschitz.webp?t=1652217183" type="image/png" medium="image" fileSize="1167463">
        <media:title type="plain">Eyal Lifschitz speaking at conference</media:title>
        <media:description type="plain">Eyal Lifschitz, co-founder of Israeli venture capital fund Peregrine Venture.</media:description>
      </media:content>
    </item>
  </channel>
</rss>
